Introduction
The diversity of proteins, enzymes and biologically active peptides found in snake venoms influences the wide range of biological processes destabilized during envenoming. In Viperidae snakes, these effects can be categorized in local damage or systemic injury. Local damage results mainly from enzymes such as phospholipases A 2 which produces myonecrosis and edema (1) and metalloproteinases that destroys the endothelium, components of vascular wall and extravascular matrix, causing vascular permeability disorders. The systemic effects are those related to the disruption of the hemostatic equilibrium of blood coagulation and hemorrhage caused by other metalloproteinases, serinoproteinases, disintegrins and type C lectins (2) . Another common effect observed in these envenomings is hypotension, first known to be a consequence of bradykinin potentiating peptides (BPPs) 2 , described and cloned in B. jararaca venom (3, 4) . These peptides inhibit angiotensin converting enzyme (ACE EC3. 4.15.1) and enhances bradykinin action, generated by proteolytic cleavage of host proteins by venom proteases. Kallikrein-like enzyme is one of them, which promotes kinins release from kininogen, increasing capillary permeability (5) . Despite the well-characterized action mechanisms of BPPs, it was established that other factors present in the venoms also act as hypotensive agents.
For instance, the presence of natriuretic peptides was described by protein chemistry and cDNA cloning studies (4, (6) (7) (8) .
In Vipera aspis venom, a hypotensive factor (HF) was described as being a potent nonlethal decreasing pressure protein (9) . The identity of this toxin and of ICPP (10) , a related polypeptide from Vipera lebentina, remained unknown until its amino acid sequence was uncovered by Edman sequencing, showing a strong similarity with vascular endothelium growth factor (VEGF) (10, 11) . The biological properties of HF, besides the hypotension, includes the angiogenic effects and the vascular permeability increasing capability of typical VEGFs (11) .
The VEGF family of proteins is composed by several members, including the VEGF, first known as vascular permeability factor (VPF) (12) , the placental growth factor (PlGF) and platelet-derived growth factor (PDGF). They are dimeric proteins composed of two identical or structurally related subunits linked by two inter-chain disulfide bridges. VEGFs act through binding to specific tyrosine-kinases receptors VEGFR-1 (flt-1), VEGFR-2 (KDR/flk-1) and/or VEGFR-3 (flt-4), which are mainly expressed in endothelial cells (see reviews in [13] [14] [15] .
Human VEGF gene is composed of 8 exons that can be alternatively spliced resulting in five Cterminal truncated isoforms of monomeric proteins named by their length in amino acids of the mature protein, VEGF 121 , VEGF 145 , VEGF 165 , VEGF 189 and VEGF 206 (13, 16) . The shorter forms are released into the blood. The longer ones stay adsorbed to the extracellular matrix of cell surfaces through heparin-like proteoglycans molecules that binds to the basic amino acid residues localized at the carboxi-terminus of the longest VEGF forms (17) . The distribution of VEGF occurs throughout vertebrates, being found and cloned in zebrafish, plasmidial DNA purified and sequenced on a ABI 377 using BigDye2 dideoxyterminators (Applied Biosystems). The primers used to sequence were M13 forward and M13 reverse. Generated ESTs were compared to GenBank nucleotide and protein databases using Blastn and Blastx programs at NCBI to identify putative gene products. Complete DNA sequence was obtained by primer-walking and deposited at GenBank under accession number AY033151.
Sequence analysis was performed by using Vector NTI Suite software (Informax).
Northern Blot Assay -Total RNAs from several tissues and snakes were isolated as described above (cDNA library construction). 10 µg of total RNAs were fractionated on denaturant 1% agarose/formaldehyde gel, transferred to a nylon membrane (Genescreen, NEN) and fixed by baking at 80°C for 2 hours. The probe was obtained by digestion of clone GH027
by EcoRI and HindIII restriction enzymes. The svVEGF fragment was isolated after agarose gel electrophoresis and labeled by random primer extension, using digoxigenin (DIG) labeled dNTPs (Boehringer). The membrane was incubated with denatured DIG-labeled probe diluted in hybridization buffer (50% formamide, 5 X SSC, 5 X Denhardt's, 0,1% N-laurilsarcosine and 100µg/ml salmon sperm DNA) at 42°C for 16h. The membrane was washed twice with 2X SSC / 0,1% SDS at 20°C for 5 minutes and twice with 0,1X SSC / 0,1% SDS at 65°C for 15 minutes.
Detection was performed with anti-digoxigenin-alkaline-phosphatase conjugate according to manufacturer protocol and interrupted after 20 minutes of colorimetric reaction. tgctcgagcaagtgatgccctttatgga 3') was designed and contained a XhoI restriction site and the nucleotide sequence coding the first seven amino acids of the putative mature protein (Fig.1) .
The reverse primer used was SP6 (5' atttaggtgacactatag 3') which anneals to the SP6 promoter located in the pGEM11Zf+ vector. The PCR product was cloned into pGEM-T plasmid (Promega). Plasmidial DNA containing the mature svVEGF insert was digested with XhoI and HindIII enzymes. The excised insert was subcloned in the same sites of pAE expression vector 4 , a plasmid derived from pRSET (Invitrogen) and pET 3-His (24) plasmids, resulting in the pAE-msvVEGF construct. The correct cloning was confirmed by sequencing. The recombinant mature svVEGF (rmsvVEGF) was expressed with additional eight amino acids fusioned at Nterminus, including a 6XHis-tag. For the production of rmsvVEGF, transformed E. coli BL21 (DE3) cells were inoculated in 100 ml of LB/amp and grown overnight at 37 °C. In the next day, the culture was diluted with 2 X YT medium to 1 L and grown until the OD at 600 nm reached 0,6. At this moment, IPTG was added to a final concentration of 0,5 mM and the induced culture was incubated for additional 2h. The cells were then collected by centrifugation. Bacterial pellet was ressuspended in TIN buffer (100 mM Tris-HCl pH 8,0; 5 mM imidazole and 300 mM NaCl) and disrupted by french-pressure. Inclusion bodies were harvested by centrifugation, washed with 2M urea in TIN buffer. rmsvVEGF was extracted with extraction buffer (100 mM Tris-HCl pH 8,0; 300 mM NaCl, 8 M urea and 5 mM imidazole) for 12 hours and clarified by centrifugation. The supernatant was loaded onto a Ni 2+ -sepharose column (AmershamPharmacia). The column was washed with 10 volumes of extraction buffer, followed by 10 volumes of wash buffer (extraction buffer + 60 mM imidazole) and rmsvVEGF was eluted with elution buffer (extraction buffer + 1 M imidazole). Fractions of 1 ml were collected and analyzed in SDS-PAGE.
Protein refolding was achieved essentially as described (25) . Ten mg of unfolded rmsvVEGF, determined by Coomassie Blue (26) , were pooled, diluted to a final concentration of 0,5 mg/ml in 20 mM Tris pH 8,0, 6M guanidine hydrochloride, 10 mM DTT and incubated for 3 hours, at room temperature. 20 ml of this solution was dialyzed against 250 ml of 20 mM TrisHCl pH 8,0, 2M urea, containing 2 mM reduced glutathione (GSH) and 0,5 mM oxidized glutathione (GSSG) for 24 hour at 4°C. The dialysis buffer was changed to 500 ml of 20 mM Tris pH8,0 and kept dialyzing overnight at 4°C. The insoluble material was removed by centrifugation and the soluble refolded protein was extensively dialyzed against PBS. The mixture of monomers and dimers was separated by heparin-sepharose chromatography as described (11) . The protein mixture was adsorbed on the resin in PBS, washed by PBS and the refolded rmsvVEGF dimers were eluted with PBS containing 300 mM NaCl .
rmsvVEGF Antiserum Generation -Ten male Swiss mice (20g/animal) were immunized with 15 µg of unfolded rmsvVEGF. The protein was injected i.p. in 500 µl of PBS buffer containing 10% (w/v) Al(OH) 2 used as adjuvant. After 15 days, the animals were injected with a booster dose of additional 15 µg of the protein. In the 30 th day, they were bled from periorbital artery and the serum extracted by centrifugation after clothing. The serum title was followed by ELISA.
Western-Blotting -Samples of snake venoms obtained from Herpetology Department, Instituto Butantan, cellular extracts and recombinant rmsvVEGF were resolved in 15% SDS-PAGE in both reducing or non-reducing conditions and blotted onto nitrocellulose membranes.
The membranes were stained with Ponceau S, blocked with 5% non-fat milk, incubated with the anti-rmsvVEGF serum at 1:500 dilution in PBS/0,5% Tween 20 for 2 hours, washed and incubated with horse-peroxidase-conjugated anti-mouse IgG (Sigma) for 1 hour. The blot was revealed using DAB (LifeTechnologies) after metal ion enhancement with CoCl 2 .
Screening of Bothrops jararaca cDNA Library for VEGF cDNA -A cDNA library from
B. jararaca venom glands (27) was constructed as described above for B. insularis cDNA library.
The svVEGF cDNA from B. jararaca venom gland was isolated by PCR using the forward svVEGF-M primer and the SP6 primer described above (Recombinant Protein Expression Section). These primers would hybridize respectively to the svVEGF cDNA and to the SP6 promoter at pGEM11Zf(+) plasmid used to construct the library. The amplified DNA was further subcloned in pGEM-T (Promega) and completely sequenced as described above. To obtain the complete cDNA sequence containing the 5'UTR and the signal peptide, a PCR was performed using B. jararaca cDNA library as a template and the svVEGF reverse primer (5' acids, according to Nielsen's algorithm (30) and is in accordance with the N-terminal amino acid sequence alignment of HF protein characterized from V. aspis snake venom (11) (Fig. 2) . A molecular mass of 13,8 kDa and pI of 8,19 were predicted for the putative mature protein. to Danio rerio (64,2%) than to human VEGFs (60,0%). PlGFs and VEGF-B are less similar to svVEGFs, but showed some conserved structural features. The main characteristic of VEGF/PlGF family is the presence of the three intra-chain and the two inter-chain disulfide bridges. svVEGF possesses all the 8 cysteine residues involved in the disulfide bridges formation, thus suggesting its ability to dimerize through the formation of the same intra and inter disulfide bonds. The deduced signal peptide is shorter (Fig. 2) and the putative mature protein displays the hydrophobic residues Val 2 , Phe 5 , Met 6 which have been shown to participate in an amphipathic α-helix that stabilize the dimerization of human VEGF (31) . The methionine at position 3 would participate in that process in the place of the valine in this same position in VEGF 121 . Val 3 was also shown to be an important amino acid residue in the dimerization of human VEGF. Except for Glu 7 , none of the other charged residues are observed in the N-terminus. The C-terminus is different from that of HF protein and longer than the shortest isoforms of VEGF/PlGF. The glycosylation site presented in some VEGFs (Fig. 2) is absent in svVEGF.
Results

Identification and Characterization of Snake
Production of Recombinant Mature svVEGF (rmsvVEGF) -To determine its
biochemical and biological properties, rmsvVEGF was expressed in E. coli. A cDNA fragment coding the mature protein was amplified by PCR, cloned in pGEM-T system (Promega) and subcloned in the T7 based promoter pAE plasmid 4 . The final construct encodes a N-terminally fused sequence containing a 6Xhis-tag and two amino acid residues derived from Xho I restriction site. The 17kDa rmsvVEGF monomer was clearly visible in the extracts of induced or uninduced E. coli BL21 (DE3) cells transformed with pAE-msvVEGF for two hours by IPTG (Fig. 3a) . Overnight inductions were also efficient in rmsvVEGF expression, producing up to 50 mg of the recombinant protein. The protein was expressed in the cells as inclusion bodies. The protein in the inclusion bodies was solubilized by urea and further purified by Ni ++ -chelating affinity chromatography, resulting in 30 mg of purified monomers (Fig. 3a) .
Since VEGFs are active just in the dimerized forms through intra-and inter-disulfide bonds (32), several attempts to refold the monomers were done. The best results were achieved by using oxidizing/reducing pair of 2mM GSH and 0,5mM GSSG, before urea removing as essentially described (25) . Although some protein loss occurs due to precipitation after urea remove, this procedure could dimerize about 20% of monomeric mature svVEGF, producing a final yield of 2 mg of refolded protein from 10 mg of monomers (Fig. 3b) . To purify the refolded dimeric rmsvVEGF from monomeric forms, we raised the possibility that rmsvVEGF could bind to heparin-sepharose like HF protein and some VEGF forms. The binding to heparin-sepharose is not a general rule for VEGFs. Human VEGF 121 does not bind to heparin-sepharose whereas VEGF 189 binds strongly and VEGF 165 binds with intermediary affinity, being eluted with 0,9 M NaCl (33) . In the case of rmsvVEGF, our results showed that it has a relatively weak affinity for heparin-sepharose, being eluted with 0,3 M NaCl (Fig. 3b) .
Expression of svVEGF in Other Snake Venoms and Tissues -Anti-rmsnVEGF
antiserum was generated in mice, against the unfolded rmsvVEGF. This antiserum was able to recognize in Western-blot the reduced (17 kDa) monomeric form of rmsvVEGF in reducing SDS-PAGE condition (lane 1, Fig. 4 
), but not the refolded (30 kDa) dimeric form in SDS-
PAGE in non reducing condition (data not shown).
To investigate the biological distribution of svVEGF, Western-blots were performed with samples of some Viperidae and Elapidae snake venoms. These include the venoms from B. Fig. 4) . In contrast, extracts of the B. insularis heart tissue, did not present any immunoreactive band (lane 9, Fig. 4) . It was shown that heart, lung, kidney and other organs from adult vertebrates are typical VEGF expressing tissues (34) . This result suggests that the svVEGF is a snake venom component and its expression is specific to the snake venom glands. These results were also confirmed by Northern-blot studies. A 1.3 kb transcript was detected in the venom glands of B. insularis, B. jararaca and C. durissus terrificus, but not in the B. insularis lung, carotid artery, pancreas and maxillary muscle tissues (Fig. 5) .
insularis, B. jararaca, B. jararacussu and Crotalus durissus terrificus (Viperidae) as well as the
Cloning of svVEGF from B. jararaca -Since the western-blot and northern-blot results
indicated an ubiquitous distribution of svVEGF in snake venoms and no other nucleotide sequence of snake VEGFs had been described, we decide to clone the svVEGF cDNA from B. jararaca for comparison to B. insularis svVEGF. B. jararaca snake bite represents the main cause of snake envenoming accidents in Brazil (35) . The entire cDNA sequence of B. jararaca svVEGF was obtained after PCR, using the B. jararaca venom gland cDNA library (27) as a template and the oligos described in Experimental Procedures. All the sequences were clustered and the B. jararaca svVEGF cDNA sequence was obtained by superposing the sequenced fragments.
The nucleotide sequence of Bothrops jararaca svVEGF (supplement, Fig. I ) is quite similar to B. insularis svVEGF cDNA sequence, differing in just few nucleotides in the coding region and some gaps and insertions sequences at 5' and 3' UTR. The amino acid sequence is also very similar between the two botropic svVEGFs (Fig. 2) , presenting 93% of identity. Biological activity of svVEGF -An increase in vascular permeability is one of the earliest biological effects of the VEGF action in vivo. This activity was investigated by Miles assay (28) using refolded rmsvVEGF. Refolded rmsvVEGF was injected intradermally in the mice backs. As a control, equivalent volume of PBS was injected below the site of refolded rmsvVEGF inoculation in the same animal. The ability of rmsvVEGF to produce blue spots is due to leaking of systemic Evan's Blue (see Experimental Procedures) and is clearly observed in figure 6 . The dose dependent effect was observed in mice injected with different doses of refolded rmsvVEGF (Fig. 6A) . The extrusion of the albumin dye complex was detected as early as 5 minutes after inoculation of rmsvVEGF and did not increase after 15 minutes (Fig. 6B) .
Comparing HF protein from
Discussion
During the sequencing of abundant ESTs from the B. insularis venom gland cDNA library, we have characterized a cDNA coding for a protein with high identity to vertebrate VEGFs, including human VEGFs. This is the first nucleotide sequence reported for a VEGF derived from the snake venom gland. The major goal of this EST project, is to define the transcripts that characterize this specialized tissue in B. insularis. B. insularis is an endemic snake restricted to the Island of Queimada Grande. In contrast to other bothropic snakes, its diet consists mainly of birds and some invertebrates (36) . For this reason, B. insularis venom might present some specific toxins selected over time to better capture this kind of prey. As a consequence, we would expect to describe novel transcribed sequences from B. insularis venom glands of seminal importance for the venom gland physiology and function. In addition, this approach would also lead to the description of new putative toxins. The characterization of svVEGF is an example of such reverse biology effort (7) . The svVEGF protein is a new venom component described in B. insularis and possesses several of the vertebrate VEGF features, including the eight cysteines in the conserved positions. These cysteines are responsible for the inter-and intra-molecular disulfide bridges characteristic of this family of proteins. The presence of svVEGF in other snake venoms investigated here was also shown through Westernblot (Fig. 4) , Northern-blot (Fig. 5) and cDNA cloning and sequencing of B. jararaca svVEGF (Fig. 2 and Supplemental data). Recently, a heparin-binding hypotensive factor (HF) with vascular permeability activity and mitogenic activity on endothelial cells was structurally characterized as a VEGF-like protein in the venom of V. aspis aspis by complete amino acid sequencing by Edman degradation (11) . A similar protein (ICPP) was also partially characterized from the venom of V. lebetina with vascular permeability activity that also resembles the VEGF family of proteins (10) . Our data extend these results and help to establish that VEGFs are venom components distributed not only in Viperidae but also in Elapidae snake venoms. Furthermore, the Western-and Northern-Blot studies showed that the expression of svVEGF is specific to the venom glands and may represent a distinct VEGF transcript/protein from other VEGFexpressing tissues like heart, lung and kidney. Like HF protein, the refolded rmsvVEGF from B.
insularis also possesses a weak affinity for heparin-sepharose resin, being step-eluted with 0,3 M NaCl in PBS. We would expect that binding to heparan-molecules occurs under physiological conditions in vivo and such kind of interaction would play some role in the activity of svVEGFs. This notion is supported by the results showing that the mitogenic activity of HF protein was inhibited by an excess of heparin molecules in bovine aorthic endothelial cells (11) . The cellassociated heparan molecules in the membrane would facilitate the presentation of svVEGFs to their receptors (37). We do not know which receptor mediates the effect of svVEGFs or if they bind to the VEGFR-1 (flt-1) (38), VEGFR-2 (flk-1/KDR) (39), VEGFR-3 (flt4) (19) or to neuropilin -1 (40) . The three first proteins are tyrosine kinase receptors that bind different VEGF forms. Neuropilin-1 functions as an axon guidance factor receptor for the collapsin/semaphorin family of proteins (41, 42) and enhances both the binding of VEGF 165 to VEGFR-2 and VEGF 165 -mediated chemotaxis (40) , suggesting that neuropilin-1 may be a co-receptor for VEGFR-2.
The receptor(s) responsible for mediating vascular permebility is unknown. However, the fact that all of the VEGF family members which have this activity bind to VEGFR-2, suggests that this receptor (and neuropilin-1?) may be involved (14) . In addition, a mutant of VEGF-C which can not bind VEGFR-2 loses the ability to induce vascular permeability (43) . Nevertheless, the description of a VEGF mutant that can not bind to VEGFR-2 but induces vascular permeability supports the existence of a novel receptor not identified so far (14) . Since the rmsvVEGF described here possesses vascular permeability activity, it is possible that this response would be mediated by VEGFR-2 or by a novel receptor. Further studies on svVEGF receptors would be necessary to clarify this question. It is interesting that the vascular permeability activity induced by HF protein (5 ng) is more than ten times higher than its mitogenic effects on endothelial cells (half-maximal response around 125 ng/ml). For this reason, the increase in capillar permeability can be considered the primary action of svVEGFs, including the svVEGFs described here, the HF and ICCP proteins (10, 11) . 
